STRATA Skin Sciences, Inc. (SSKN) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
SSKN currently has 5.89M outstanding shares. with significant dilution risk as 7.28M authorized shares could dilute existing holders by 123.6%. The company has significantly diluted shareholders by 72.97% over the past 2 years, indicating aggressive capital raising. Recent corporate actions include 1 stock split (positive for accessibility) and 1 reverse split (concerning signal).
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Nov 14, 2025 |
10-Q filing | 5.9M shares outstanding |
5.9M | 7.3M |
| May 15, 2025 |
10-Q filing | 4.2M shares outstanding |
4.2M | 9M |
| Mar 28, 2025 |
10-K filing | 3.8M shares outstanding |
3.8M | 9.4M |
| Dec 05, 2024 |
S-3/A filing: STRATA Skin Sciences, Inc. may offer and sell from time to time, in one or more series, common stock, preferred stock, and debt securities for a total of $25,000,000. |
4.2M | 9M |
| Nov 22, 2024 |
S-3 filing: STRATA Skin Sciences, Inc. files an S-3 form to register the potential offering and sale of common stock, preferred stock and debt securities up to an aggregate amount of $25,000,000. |
4.2M | 660K |
| Nov 14, 2024 |
10-Q filing | 4.0M shares outstanding |
4M | 800K |
| Aug 14, 2024 |
10-Q filing | 4.2M shares outstanding |
4.2M | 660K |
| Jun 06, 2024 |
Stock Split
8-K filing: Stock split 1-for-10 | Outstanding: 35,060,920 → 3,506,092 |
3.5M | 1.3M |
| May 15, 2024 |
10-Q filing | 35.1M shares outstanding |
35M | 13M |
| Mar 28, 2024 |
10-K filing | 34.9M shares outstanding |
35M | 13M |
| Nov 14, 2023 |
10-Q filing | 34.9M shares outstanding |
35M | 13M |
| Aug 09, 2023 |
S-3 filing: This S-3 filing pertains to an offering of 800,000 shares of common stock issuable upon the exercise of a warrant by a selling stockholder, with the company not receiving any proceeds from the sale, except upon cash exercise of the warrant, which would be used for working capital and general corporate purposes. |
35M | 13M |
| Aug 09, 2023 |
10-Q filing | 34.9M shares outstanding |
35M | 13M |
| Jul 06, 2023 |
8-K filing: STRATA Skin Sciences, Inc. entered into Amendment No. 3 to its Credit and Security Agreement with MidCap Financial Trust, an Amended and Restated Warrant Agreement with MidCap Funding XXVII Trust to purchase 800,000 shares of common stock at an exercise price of $0.88, an Amended and Restated Registration Rights Agreement, and a Fee Letter Agreement. |
35M | 13M |
| May 15, 2023 |
10-Q filing | 34.9M shares outstanding |
35M | 13M |
| Mar 31, 2023 |
10-K filing | 34.7M shares outstanding |
35M | 13M |
| Nov 09, 2022 |
10-Q filing | 34.7M shares outstanding |
35M | 13M |
| Aug 10, 2022 |
10-Q filing | 34.7M shares outstanding |
35M | 13M |
| May 11, 2022 |
10-Q filing | 34.7M shares outstanding |
35M | 13M |
| Mar 21, 2022 |
10-K filing | 34.1M shares outstanding |
34M | 14M |
| Jan 13, 2022 |
S-3 filing: This S-3 filing registers 358,367 shares of common stock offered by selling stockholders. The company will not receive any proceeds from the sale. |
35M | 13M |
| Jan 10, 2022 |
8-K filing: STRATA Skin Sciences, Inc. acquired assets from Theravant Corporation, paying $500,000 in cash and issuing 358,367 shares of its common stock as part of the purchase price. |
34M | 13M |
| Nov 22, 2021 |
S-3/A filing: This S-3/A filing from STRATA Skin Sciences, Inc. relates to the offering of 373,626 shares of common stock issuable upon the exercise of a warrant. |
34M | 13M |
| Nov 16, 2021 |
S-3 filing: This S-3 filing from STRATA Skin Sciences, Inc. relates to the offering of common stock by selling stockholders upon the exercise of warrants, with the company not receiving any proceeds from the sale but potentially receiving proceeds upon cash exercise of the warrants for working capital and general corporate purposes. |
34M | 13M |
| Nov 12, 2021 |
10-Q filing | 34.2M shares outstanding |
34M | 13M |
| Oct 12, 2021 |
S-3/A filing: STRATA Skin Sciences, Inc. is offering various securities, including common stock, preferred stock, debt securities, warrants, rights, and units, for total gross proceeds up to $25,000,000. |
34M | 12M |
| Oct 04, 2021 |
8-K filing: STRATA Skin Sciences, Inc. entered into a credit agreement for a $8.0 million term loan and issued a warrant to purchase 373,626 shares of common stock at an exercise price of $1.82. |
34M | 6.8M |
| Aug 16, 2021 |
10-Q filing | 33.9M shares outstanding |
34M | 6.8M |
| Aug 13, 2021 |
S-3 filing: STRATA Skin Sciences, Inc. may offer and sell common stock, preferred stock, debt securities, warrants, rights, or units for total gross proceeds up to $9,454,912. |
34M | 6.8M |
| May 13, 2021 |
10-Q filing | 33.8M shares outstanding |
34M | 0 |
| Mar 25, 2021 |
10-K filing | 33.6M shares outstanding |
34M | 0 |
| Nov 10, 2020 |
10-Q filing | 32.9M shares outstanding |
33M | 0 |
| Aug 12, 2020 |
10-Q filing | 33.7M shares outstanding |
34M | 0 |
| May 13, 2020 |
10-Q filing | 33.2M shares outstanding |
33M | 0 |
| Mar 17, 2020 |
10-K filing | 32.0M shares outstanding |
32M | 0 |